{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:20:48Z","timestamp":1783405248815,"version":"3.54.6"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) is commonly interpreted as a compensatory response to disturbances in mineral metabolism, yet this view does not fully account for the biochemical instability and treatment resistance observed in advanced disease. Current therapeutic strategies primarily target individual regulatory pathways. Calcimimetics suppress parathyroid hormone (PTH) secretion through calcium-sensing receptor (CaSR) activation, whereas active vitamin D analogs reduce PTH synthesis via vitamin D receptor (VDR) signaling but are frequently associated with increased mineral load and elevated fibroblast growth factor 23 (FGF-23). Nutritional vitamin D (NVD) restores circulating 25-hydroxyvitamin D [25(OH)D] and supports tissue-level activation of vitamin D pathways without substantial increases in calcium or phosphate. When combined with calcimimetics, NVD provides complementary modulation of PTH regulation through distinct but interacting mechanisms. Experimental and clinical evidence suggests that this combination may enhance responsiveness of parathyroid tissue and contribute to improved biochemical control. At the system level, this approach has been associated with reduced PTH variability, relatively stable calcium balance, stabilization or modest reduction in phosphate, and reduction in FGF-23 compared with active vitamin D\u2013based strategies. However, current evidence remains largely based on surrogate biochemical endpoints. The Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial, the largest Randomized Controlled Trial (RCT) of cinacalcet in dialysis patients, demonstrated no significant reduction in the primary composite endpoint of all-cause mortality or major nonfatal cardiovascular events in the intention-to-treat analysis despite consistent biochemical improvements, and the extent to which combination calcimimetic-based therapy translates into improved long-term clinical outcomes therefore remains uncertain.<\/jats:p>","DOI":"10.3389\/fnut.2026.1871009","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:46:26Z","timestamp":1783403186000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination therapy with nutritional vitamin D and calcimimetics in secondary hyperparathyroidism: a mechanism-based approach to restoring PTH regulation"],"prefix":"10.3389","volume":"13","author":[{"given":"Chien-Lin","family":"Lu","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University","place":["New Taipei City, Taiwan"]},{"name":"School of Medicine, College of Medicine, Fu Jen Catholic University","place":["New Taipei City, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chou","family":"Hou","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, Fu Jen Catholic University","place":["New Taipei City, Taiwan"]},{"name":"Division of Nephrology, Department of Internal Medicine, Cardinal-Tien Hospital","place":["New Taipei City, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chao","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Chao","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University","place":["Taipei, Taiwan"]},{"name":"Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei Medical University","place":["Taipei, Taiwan"]},{"name":"Taipei Medical University-Research Center of Urology and Kidney, Taipei Medical University","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Mei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University","place":["Taipei, Taiwan"]},{"name":"Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University","place":["New Taipei City, Taiwan"]},{"name":"TMU Research Center of Urology and Kidney, Taipei Medical University","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Cheng","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University","place":["New Taipei City, Taiwan"]},{"name":"Division of Nephrology, Department of Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","place":["New Taipei City, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000486060","article-title":"Physiology of the calcium-parathyroid hormone-vitamin D axis","volume":"50","author":"Goltzman","year":"2018","journal-title":"Front Horm Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14341\/osteo13142","article-title":"The role of the calcium-sensing receptor in the regulation of parathyroid hormone secretion in physiology and in calcitropic diseases","volume":"26","author":"Marmalyuk","year":"2024","journal-title":"Osteopor Bone Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/sj.ki.5002287","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics","volume":"74","author":"Goodman","year":"2008","journal-title":"Kidney Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"30337","DOI":"10.1074\/jbc.M201804200","article-title":"Human calcium-sensing receptor gene","volume":"277","author":"Canaff","year":"2002","journal-title":"J Biol Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2042018820974172","DOI":"10.1177\/2042018820974172","article-title":"Serum PTH levels in dialysis: better safe than sorry","volume":"11","author":"Cozzolino","year":"2020","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3803\/EnM.2024.1978","article-title":"Roles of parathyroid hormone and fibroblast growth factor 23 in advanced chronic kidney disease","volume":"39","author":"NakagawaY","year":"2024","journal-title":"Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/j.1523-1755.2000.00370.x","article-title":"Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism","volume":"58","author":"Yano","year":"2000","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1038\/s41467-019-12399-9","article-title":"Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion","volume":"10","author":"Centeno","year":"2019","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/nu10121890","article-title":"The emerging role of nutritional vitamin D in secondary hyperparathyroidism in CKD","volume":"10","author":"Lu","year":"2018","journal-title":"Nutrients"},{"key":"B10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1267\/ahc.25-00039","article-title":"Hypermethylation of the p16INK4a promoter as an early epigenetic event in nodular hyperplasia associated with secondary hyperparathyroidism","volume":"58","author":"Kitazawa","year":"2025","journal-title":"Acta Histochem Cytochem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"E720","DOI":"10.1152\/ajpendo.00517.2015","article-title":"Molecular patterns of diffuse and nodular parathyroid hyperplasia in long-term hemodialysis","volume":"311","author":"T\u00fdcov\u00e1","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B12","first-page":"S42","article-title":"Histopathology and pathophysiology of secondary hyperparathyroidism due to chronic renal failure","volume":"44","author":"Tominaga","year":"1995","journal-title":"Clin Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22636.1","article-title":"Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease","author":"Rodr\u00edguez-Ortiz","year":"2020","journal-title":"F1000Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1020858","DOI":"10.3389\/fphar.2022.1020858","article-title":"Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism","volume":"13","author":"Xiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1046\/j.1523-1755.2002.00585.x","article-title":"Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism","volume":"62","author":"Tokumoto","year":"2002","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13577-016-0143-9","article-title":"Hypermethylation of the CaSR and VDR genes in the parathyroid glands in chronic kidney disease rats with high-phosphate diet","volume":"29","author":"Uchiyama","year":"2016","journal-title":"Hum Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12882-020-01880-z","article-title":"Severe chronic kidney disease environment reduced calcium-sensing receptor expression in parathyroid glands of adenine-induced rats even without high phosphorus diet","volume":"21","author":"Uchiyama","year":"2020","journal-title":"BMC Nephrol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1172\/JCI32409","article-title":"The parathyroid is a target organ for FGF23 in rats","volume":"117","author":"Ben-Dov","year":"2007","journal-title":"J Clin Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/JOE-07-0267","article-title":"Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells","volume":"195","author":"Krajisnik","year":"2007","journal-title":"J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"40534","DOI":"10.1038\/srep40534","article-title":"Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease","volume":"7","author":"Kawakami","year":"2017","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/ki.2009.512","article-title":"Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients?","volume":"77","author":"Lafage-Proust","year":"2010","journal-title":"Kidney Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/jbmr.4155","article-title":"The CKD-MBD syndrome: hysteresis in PTH involvement and PTH administration for its management","volume":"35","author":"Pazianas","year":"2020","journal-title":"J Bone Miner Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"sfae423","DOI":"10.1093\/ckj\/sfae423","article-title":"Pathophysiology and therapies of CKD-associated secondary hyperparathyroidism","volume":"18","author":"Mazzaferro","year":"2025","journal-title":"Clin Kidney J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1055\/s-0041-1732495","article-title":"Analysis of the prevalence and severity of dysregulated bone mineral homeostasis in nondialyzed chronic kidney disease patients","volume":"14","author":"Patel","year":"2021","journal-title":"J Lab Physicians"},{"key":"B25","doi-asserted-by":"publisher","first-page":"12223","DOI":"10.3390\/ijms232012223","article-title":"Mineral bone disorders in kidney disease patients: the ever-current topic","volume":"23","author":"Hu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10157-023-02336-y","article-title":"Roles of PTH and FGF23 in kidney failure: a focus on nonclassical effects","volume":"27","author":"Komaba","year":"2023","journal-title":"Clin Exp Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.3390\/cimb46050241","article-title":"The molecular mechanisms underlying the systemic effects mediated by parathormone in the context of chronic kidney disease","volume":"46","author":"Maranduca","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/ndt\/gfy287","article-title":"High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease","volume":"34","author":"Carrillo-L\u00f3pez","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"B29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3390\/life14030418","article-title":"Chronic kidney disease with mineral bone disorder and vascular calcification: an overview","volume":"14","author":"Izzo","year":"2024","journal-title":"Life"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9619253","DOI":"10.1155\/2018\/9619253","article-title":"Parathyroid hormone fragments: new targets for the diagnosis and treatment of chronic kidney disease-mineral and bone disorder","volume":"2018","author":"Chen","year":"2018","journal-title":"BioMed Res Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MNH.0000000000000992","article-title":"Skeletal parathyroid hormone hyporesponsiveness: a neglected, but clinically relevant reality in chronic kidney disease","volume":"33","author":"Evenepoel","year":"2024","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ncpendmet0394","article-title":"Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease","volume":"3","author":"Brown","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1053\/ajkd.2001.28109","article-title":"Vitamin D analogues for the management of secondary hyperparathyroidism","author":"Martin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.3390\/nu14153009","article-title":"Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future","volume":"14","author":"Brandenburg","year":"2022","journal-title":"Nutrients"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1643415","DOI":"10.3389\/fmed.2025.1643415","article-title":"Vitamin D and chronic kidney disease: mechanisms, clinical implications, and future perspectives","volume":"12","author":"Wang","year":"2025","journal-title":"Front Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1681\/ASN.2007040406","article-title":"EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease","volume":"19","author":"Arcidiacono","year":"2008","journal-title":"J Am Soc Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/ndt\/gfu318","article-title":"Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice","volume":"30","author":"Arcidiacono","year":"2015","journal-title":"Nephrol Dial Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/ndt\/gfu311","article-title":"The induction of C\/EBP\u03b2 contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease","volume":"30","author":"Arcidiacono","year":"2015","journal-title":"Nephrol Dial Transplant."},{"key":"B39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","article-title":"Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis","volume":"76","author":"Palmer","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.2174\/1381612829666221027110656","article-title":"A systematic review and meta-analysis of efficacy and safety of calcimimetic agents in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease","volume":"28","author":"Liu","year":"2022","journal-title":"Curr Pharm Des."},{"key":"B41","doi-asserted-by":"publisher","first-page":"CD006254","DOI":"10.1002\/14651858.CD006254.pub2","article-title":"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients","volume":"2014","author":"Ballinger","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ph15080952","article-title":"Role of calcimimetics in treating bone and mineral disorders related to chronic kidney disease","volume":"15","author":"Hou","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ncpneph0977","article-title":"Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?","volume":"5","author":"Wetmore","year":"2008","journal-title":"Nat Clin Pract Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.23876\/j.krcp.19.041","article-title":"Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease","volume":"38","author":"Abbas","year":"2019","journal-title":"Kidney Res Clin Pract."},{"key":"B45","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/nu9040328","article-title":"Vitamin D in chronic kidney disease and dialysis patients","volume":"9","author":"Jean","year":"2017","journal-title":"Nutrients"},{"key":"B46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/vec.12036","article-title":"Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease","volume":"23","author":"de Brito Galvao","year":"2013","journal-title":"J Vet Emerg Crit Care"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"EVOLVE Trial","year":"2012","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"Cd006254","DOI":"10.1002\/14651858.CD006254.pub2","article-title":"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients","volume":"2014","author":"Ballinger","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00228-024-03730-5","article-title":"Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis","volume":"80","author":"Liu","year":"2024","journal-title":"Eur J Clin Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"12357","DOI":"10.1111\/sdi.12357","article-title":"The use of calcimimetics for the treatment of secondary hyperparathyroidism: a 10 year evidence review","volume":"28","author":"Rodr\u00edguez","year":"2015","journal-title":"Semin Dial"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.3390\/nu14235186","article-title":"Interaction of vitamin D with peptide hormones with emphasis on parathyroid hormone, FGF23, and the renin-angiotensin-aldosterone system","volume":"14","author":"Latic","year":"2022","journal-title":"Nutrients"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/ckj\/sfab035","article-title":"Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis","volume":"14","author":"Bover","year":"2021","journal-title":"Clin Kidney J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1681\/ASN.2009080815","article-title":"Reduced hepatic synthesis of calcidiol in uremia","volume":"21","author":"Michaud","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/jbmr.3686","article-title":"Obesity decreases hepatic 25-hydroxylase activity causing low serum 25-hydroxyvitamin D","volume":"34","author":"Roizen","year":"2019","journal-title":"J Bone Miner Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e111265","DOI":"10.1371\/journal.pone.0111265","article-title":"The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers","volume":"9","author":"Ekwaru","year":"2014","journal-title":"PLoS ONE"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1007\/s00198-016-3574-y","article-title":"25-hydroxycholecalciferol response to single oral cholecalciferol loading in the normal weight, overweight, and obese","volume":"27","author":"Camozzi","year":"2016","journal-title":"Osteoporos Int."},{"key":"B57","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1159\/000524289","article-title":"Extended-release calcifediol effectively raises serum total 25-hydroxyvitamin D even in overweight nondialysis chronic kidney disease patients with secondary hyperparathyroidism","volume":"53","author":"Bishop","year":"2022","journal-title":"Am J Nephrol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00223-021-00844-1","article-title":"Vitamin D supplementation for patients with chronic kidney disease: a systematic review and meta-analyses of trials investigating the response to supplementation and an overview of guidelines","volume":"109","author":"Christodoulou","year":"2021","journal-title":"Calcif Tissue Int."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1017\/S000711451600427X","article-title":"Cholecalciferol v ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial","volume":"116","author":"Wetmore","year":"2016","journal-title":"Br J Nutr"},{"key":"B60","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/ndt\/gfi186","article-title":"The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells","volume":"21","author":"Brown","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B61","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1677\/JME-10-0128","article-title":"Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor","volume":"46","author":"Ritter","year":"2011","journal-title":"J Mol Endocrinol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jsbmb.2014.11.022","article-title":"Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation","volume":"148","author":"Petkovich","year":"2015","journal-title":"J Steroid Biochem Mol Biol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ndt\/gfae293","article-title":"The role of nutritional vitamin D in chronic kidney disease-mineral and bone disorder in children and adults with chronic kidney disease, on dialysis, and after kidney transplantation-a European consensus statement","volume":"40","author":"J\u00f8rgensen","year":"2025","journal-title":"Nephrol Dial Transplant."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e33477","DOI":"10.1097\/MD.0000000000033477","article-title":"Role of nutritional vitamin D in chronic kidney disease-mineral and bone disorder: a narrative review","volume":"102","author":"Shen","year":"2022","journal-title":"Medicine"},{"key":"B65","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/ckj\/sfx125","article-title":"Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes","volume":"11","author":"Pereira","year":"2017","journal-title":"Clin Kidney J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1046\/j.1523-1755.1998.00735.x","article-title":"A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure","volume":"53","author":"Antonsen","year":"1998","journal-title":"Rapid Commun Kidney Int."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e23094","DOI":"10.1096\/fj.202300209R","article-title":"Effects of evocalcet on parathyroid calcium-sensing receptor and vitamin D receptor expression in uremic rats","volume":"37","author":"Saito","year":"2023","journal-title":"FASEB J."},{"key":"B68","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000499187","article-title":"Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease","volume":"49","author":"Strugnell","year":"2019","journal-title":"Am J Nephrol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"12876","DOI":"10.1073\/pnas.0403606101","article-title":"Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1alpha,25(OH)2-vitamin D3 signaling","volume":"101","author":"Mizwicki","year":"2004","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1210\/me.2010-0442","article-title":"Vitamin D receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP)","volume":"25","author":"Menegaz","year":"2011","journal-title":"Mol Endocrinol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1053\/j.ajkd.2020.03.018","article-title":"Calcimimetics: a promise unfulfilled","volume":"76","author":"Wetmore","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2215\/CJN.04520908","article-title":"Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and\/or vitamin D derivatives","volume":"4","author":"Dr\u00fceke","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/978-3-319-32507-1_31","author":"Mazzaferro","year":"2016","journal-title":"Interaction Between Vitamin D and Calcimimetics in Chronic Kidney Disease"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1213361","DOI":"10.3389\/fendo.2023.1213361","article-title":"Molecular insights into mineralotropic hormone inter-regulation","volume":"14","author":"Pike","year":"2023","journal-title":"Front Endocrinol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e0283544","DOI":"10.1371\/journal.pone.0283544","article-title":"Effects of PTH glandular and external dosing patterns on bone cell activity using a two-state receptor model\u2014Implications for bone disease progression and treatment","volume":"18","author":"Martonov\u00e1","year":"2023","journal-title":"PLoS ONE"},{"key":"B76","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3803\/EnM.2024.1916","article-title":"Treatment of hypoparathyroidism by re-establishing the effects of parathyroid hormone","volume":"39","author":"Rejnmark","year":"2024","journal-title":"Endocrinol Metab."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00198-019-05033-3","article-title":"Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease","volume":"30","author":"Geng","year":"2019","journal-title":"Osteoporos Int."},{"key":"B78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2018.08.046","article-title":"CKD, arterial calcification, atherosclerosis and bone health: inter-relationships and controversies","volume":"278","author":"Reiss","year":"2018","journal-title":"Atherosclerosis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00223-021-00844-1","article-title":"Vitamin D supplementation for patients with chronic kidney disease: a systematic review and meta-analyses of trials investigating the response to supplementation and an overview of guidelines","volume":"109","author":"Christodoulou","year":"2021","journal-title":"Calcif Tissue Int."},{"key":"B80","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/ki.2012.193","article-title":"The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease","volume":"82","author":"Bosworth","year":"2012","journal-title":"Kidney Int."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/ki.2012.273","article-title":"Enhanced induction of Cyp24a1 by FGF23 but low serum 24,25-dihydroxyvitamin D in CKD: implications for therapy","volume":"82","author":"Dusso","year":"2012","journal-title":"Kidney Int."},{"key":"B82","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1159\/000541280","article-title":"The bone-vascular axis: a key player in chronic kidney disease associated vascular calcification","volume":"10","author":"Shen","year":"2024","journal-title":"Kidney Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.18632\/aging.102046","article-title":"The interplay between mineral metabolism, vascular calcification and inflammation in chronic kidney disease (CKD): challenging old concepts with new facts","volume":"11","author":"Viegas","year":"2019","journal-title":"Aging"},{"key":"B84","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12882-025-03992-w","article-title":"Association of aberrant mineral metabolic markers with fracture risk in chronic kidney disease: a comprehensive meta-analysis","volume":"26","author":"Liu","year":"2025","journal-title":"BMC Nephrol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.semnephrol.2014.09.008","article-title":"Adynamic bone disease: from bone to vessels in chronic kidney disease","volume":"34","author":"Bover","year":"2014","journal-title":"Semin Nephrol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2530162","DOI":"10.1080\/0886022X.2025.2530162","article-title":"Adynamic bone disorder in chronic kidney disease: meta-analysis and narrative review of potential biomarkers as diagnosis and therapeutic targets","volume":"47","author":"Chao","year":"2025","journal-title":"Ren Fail."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e0324628","DOI":"10.1371\/journal.pone.0324628","article-title":"Prolonged secondary hyperparathyroidism in adenine-induced CKD leads to skeletal changes consistent with skeletal hyporesponsiveness to PTH","volume":"20","author":"Metzger","year":"2025","journal-title":"PLoS ONE"},{"key":"B88","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MNH.0000000000000992","article-title":"Skeletal parathyroid hormone hyporesponsiveness: a neglected, but clinically relevant reality in chronic kidney disease","volume":"33","author":"Evenepoel","year":"2024","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B89","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000444423","article-title":"Calcitriol suppression of parathyroid hormone fails to improve skeletal properties in an animal model of chronic kidney disease","volume":"43","author":"Newman","year":"2016","journal-title":"Am J Nephrol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"sfae097","DOI":"10.1093\/ckj\/sfae097","article-title":"The effect of parathyroid hormone lowering by etelcalcetide therapy on calcification propensity and calciprotein particles in hemodialysis patients","volume":"17","author":"Thiem","year":"2024","journal-title":"Clin Kidney J"},{"key":"B91","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00223-020-00777-1","article-title":"Chronic kidney disease\u2014mineral and bone disorders: pathogenesis and management","volume":"108","author":"Cannata-And\u00eda","year":"2020","journal-title":"Calcif Tissue Int."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00228-024-03730-5","article-title":"Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis","volume":"80","author":"Liu","year":"2024","journal-title":"Eur J Clin Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"1","author":"Martin","year":"2012","journal-title":"Physiol Rev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"405","DOI":"10.28996\/2618-9801-2025-1-20-37","article-title":"Chronic kidney disease-mineral and bone disorder: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"107","author":"Ketteler","year":"2025","journal-title":"Kidney Int"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40620-021-01082-2","article-title":"Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease","volume":"34","author":"Ketteler","year":"2021","journal-title":"J Nephrol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/nu10121890","article-title":"The emerging role of nutritional vitamin D in secondary hyperparathyroidism in CKD","volume":"10","author":"Lu","year":"2018","journal-title":"Nutrients"},{"key":"B100","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000546615","article-title":"Extended-release calcifediol normalized 1,25-dihydroxyvitamin D and prevented progression of secondary hyperparathyroidism in hemodialysis patients in a pilot randomized clinical trial","volume":"57","author":"Bishop","year":"2025","journal-title":"Am J Nephrol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism","volume":"1","author":"Lindberg","year":"2003","journal-title":"Kidney Int."},{"key":"B102","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/CJN.03591006","article-title":"The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism","volume":"3","author":"Messa","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/nu10020196","article-title":"Cholecalciferol additively reduces serum parathyroid hormone levels in severe secondary hyperparathyroidism treated with calcitriol and cinacalcet among hemodialysis patients","volume":"10","author":"Zheng","year":"2018","journal-title":"Nutrients"},{"key":"B105","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2215\/CJN.10390917","article-title":"Parathyroidectomy in the management of secondary hyperparathyroidism","volume":"13","author":"Lau","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3390\/nu17091536","article-title":"Vitamin D deficiency and the clinical outcomes of calcimimetic therapy in dialysis patients: a population-based study","volume":"17","author":"Lu","year":"2025","journal-title":"Nutrients"},{"key":"B107","doi-asserted-by":"publisher","first-page":"dgab577","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B108","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B109","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12882-019-1639-9","article-title":"Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis","volume":"21","author":"Sun","year":"2020","journal-title":"BMC Nephrol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40620-020-00741-0","article-title":"Dialysate calcium concentration during calcimimetic treatment: a neglected issue","volume":"34","author":"Locatelli","year":"2020","journal-title":"J Nephrol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/sj.ki.5001666","article-title":"Reversal of adynamic bone disease by lowering of dialysate calcium","volume":"70","author":"Haris","year":"2006","journal-title":"Kidney Int."},{"key":"B112","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11914-019-00533-x","article-title":"Controversies in the management of secondary hyperparathyroidism in chronic kidney disease","volume":"17","author":"Bellor\u00edn-Font","year":"2019","journal-title":"Curr Osteoporos Rep."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1871009\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:46:28Z","timestamp":1783403188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1871009\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":112,"alternative-id":["10.3389\/fnut.2026.1871009"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1871009","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1871009"}}